JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Inicio・Lista de Acciones・AbCellera Biologics Inc

AbCellera Biologics Inc

Cerrado

SectorSanidad

4.49 5.65

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

4.25

Máximo

4.62

Métricas clave
By Trading Economics
Ingresos	-11M -46M
Ventas	-815K 4.2M
Margen de beneficios	-1,077.237
Empleados	596
EBITDA	16M -40M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+87.11% upside

Dividendos
By Dow Jones
Próximas Ganancias	3 nov 2025

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	681M 1.3B
Apertura anterior	-1.16
Cierre anterior	4.49

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

95 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.99 / 2.635 Soporte y Resistencia

AbCellera Biologics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

11 ago 2025, 17:49 UTC

Principales Movimientos del Mercado

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11 ago 2025, 17:18 UTC

Principales Movimientos del Mercado

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11 ago 2025, 16:25 UTC

Ganancias

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11 ago 2025, 23:50 UTC

Charlas de Mercado

Nikkei May Rise as Yen Weakens -- Market Talk

11 ago 2025, 23:42 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

11 ago 2025, 23:42 UTC

Charlas de Mercado

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11 ago 2025, 23:36 UTC

Charlas de Mercado

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11 ago 2025, 23:32 UTC

Charlas de Mercado

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11 ago 2025, 23:02 UTC

Charlas de Mercado

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11 ago 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

11 ago 2025, 20:37 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11 ago 2025, 20:37 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Bakkt Holdings 2Q Rev $577.9M >BKKT

11 ago 2025, 20:37 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11 ago 2025, 20:22 UTC

Ganancias

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11 ago 2025, 20:22 UTC

Ganancias

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11 ago 2025, 20:22 UTC

Ganancias

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11 ago 2025, 20:22 UTC

Ganancias

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11 ago 2025, 20:22 UTC

Ganancias

Exodus Movement 2Q Rev $25.8M >EXOD

11 ago 2025, 20:14 UTC

Charlas de Mercado

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11 ago 2025, 19:12 UTC

Charlas de Mercado

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11 ago 2025, 18:56 UTC

Charlas de Mercado

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11 ago 2025, 18:31 UTC

Charlas de Mercado

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11 ago 2025, 17:43 UTC

Charlas de Mercado

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11 ago 2025, 17:28 UTC

Charlas de Mercado

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11 ago 2025, 17:16 UTC

Charlas de Mercado

Commodity Longs Fall to 11-Month Low -- Market Talk

11 ago 2025, 16:42 UTC

Adquisiciones, fusiones, absorciones

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11 ago 2025, 16:27 UTC

Adquisiciones, fusiones, absorciones

BBVA Says Sabadell Offer Remains in Effect

11 ago 2025, 16:26 UTC

Adquisiciones, fusiones, absorciones

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11 ago 2025, 16:25 UTC

Adquisiciones, fusiones, absorciones

Banco de Sabadell Announced TSB Sale on July 1

11 ago 2025, 16:25 UTC

Adquisiciones, fusiones, absorciones

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Comparación entre iguales

Cambio de precio

AbCellera Biologics Inc previsión

Precio Objetivo

By TipRanks

87.11% repunte

Estimación a 12 Meses

Media 8.42 USD 87.11%

Máximo 17 USD

Mínimo 4.5 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AbCellera Biologics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para AbCellera Biologics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.99 / 2.635Soporte y Resistencia

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Sentimiento

By Acuity

95 / 374 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.